Sona Nanotech Inc (SONA) AI Stock Analysis

• Market Cap: C$36.60M
• Dividend Yield: N/A
• Average Volume (3M): 124.26K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.24
• Revenue Growth: N/A
• EPS Growth: 10.97%
• Country: CA
• Employees: 8
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): N/A
• Shares Outstanding: 114,375,250
• 10 Day Avg. Volume: 87,178
• 30 Day Avg. Volume: 124,263
• PEG Ratio: -2.88
• Price to Book (P/B): -1.80K
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -35.53
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -0.06
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: C$0.37 ▼(-8.75% Downside)
• Action: Reiterated Date: 03/19/26
• Date: Action: Reiterated 03/19/26

The score is driven primarily by very weak financial performance (no reported revenue, persistent losses, ongoing cash burn, and a weakening balance sheet with negative equity). Technical indicators are mixed but skew weak given the price below key longer-term moving averages and a negative MACD. Valuation provides limited support because the company is loss-making (negative P/E) and no dividend yield is available.

Positive Factors

Proprietary nanorod technology

Sona's stated focus on proprietary gold nanorod materials represents a durable technical differentiation: specialized nanoparticle IP can create barriers to entry, enable unique assay formats, and support licensing or partnerships. That structural tech advantage can drive long-term product value even before steady revenues.

Low absolute debt and improving trend

Modest absolute debt and a multi-year downtrend reduce near-term leverage burden and interest obligations. This conserves capacity to raise financing or secure partnerships without heavy fixed-financing costs, providing some financial flexibility versus highly leveraged peers during commercialization phases.

Targeting diagnostics and life-sciences market

The company's strategic focus on diagnostics and life-sciences aligns with structurally resilient healthcare demand and recurring consumable markets. Nanoparticle-enabled assays can scale into recurring revenue streams via reagent sales or platform adoption, supporting enduring market opportunity if commercialization succeeds.

Negative Factors

No reported revenue

Zero reported revenue across all periods is a fundamental weakness: it indicates the business model has not yet delivered commercial sales, leaving operations dependent on financing rather than cash generation. Over a 2-6 month horizon this elevates execution and funding risk for product rollout and commercialization.

Negative shareholders' equity and asset decline

Negative equity and a large decline in total assets materially weaken the balance sheet. This reduces borrowing capacity, increases refinancing risk, and constrains strategic options (M&A, capex, partnerships). Structurally, it impairs financial flexibility during the critical commercialization phase.

Persistent and accelerating cash burn

Consistent negative operating and free cash flow, with accelerating FCF decline in 2025, signals ongoing consumption of capital to sustain R&D and operations. This structural cash-burn requires frequent financing or dilution, limiting runway for product development and increasing long-term execution risk absent revenue traction.

Sona Nanotech Inc Business Overview & Revenue Model

Company Description

Sona Nanotech Inc., nanotechnology life sciences company, manufactures and sells gold nanorod products for diagnostic tests. The company also provides Nanotech COVID-19 Lateral Flow Assay, an immunochromatographic assay for the detection of the spike protein antigen from SARS-CoV-2 in saliva specimens from individuals, who are suspected of COVID-19; Gemini gold nanorods; Omni gold nanorods for medical applications; and contract services. Its products are used in various applications, including drug delivery, food and beverage testing, environmental testing, cell imaging, cancer treatment, and liposuction therapy, as well as medical and consumer, military, and veterinary diagnostics. The company is based in Halifax, Canada.

How the Company Makes Money

null

Sona Nanotech Inc Financial Statement Overview

Summary

Financials are very weak: revenue is reported as 0 across all annual periods shown, gross profit is consistently negative, and net losses persist with 2025 worse than 2024. Cash flow shows ongoing and worsening free-cash-flow burn in 2025, and the balance sheet deteriorated as equity turned slightly negative and assets fell sharply, increasing financing risk.

Income Statement

The income statement is very weak: reported revenue is 0 across all annual periods provided (2020–2025), while gross profit is consistently negative, implying ongoing costs without offsetting sales. Losses remain large every year, and the 2025 annual net loss worsened versus 2024 (about -$3.25M vs. -$2.70M), indicating no clear path to profitability based on the disclosed figures. The main strength is that losses have been far smaller than the extreme 2021 loss, but the company is still structurally unprofitable in the most recent year.

Balance Sheet

Leverage is mixed but the balance sheet deteriorated materially in the most recent year. Total debt is relatively modest in absolute dollars (about $308K in 2025), but stockholders’ equity turned slightly negative in 2025 (about -$39K) after being positive in 2024 (about $2.51M), which increases financial risk and reduces flexibility. Total assets also fell sharply from 2024 to 2025 (about $3.75M to $1.33M). A positive is that debt balances have generally trended down since 2020, but the negative equity in the latest period is a significant weakness.

Cash Flow

Cash flow quality is poor due to persistent cash burn. Operating cash flow and free cash flow are negative every year shown, and 2025 free cash flow declined versus 2024 (roughly -$1.96M with a -28.6% growth rate), signaling accelerating burn. A relative positive is that free cash flow roughly tracks net income (loss) in most years (i.e., losses are not being masked by strong cash generation), but the company still requires funding to sustain operations given ongoing negative operating cash flow.

Breakdown	Oct 2025	Jan 2025	Jan 2024	Jan 2023	Jan 2022
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-720.00K	-733.98K	-457.00K	-60.32K	-65.59K
EBITDA	-2.72M	-2.00M	-2.02M	-2.34M	-10.38M
Net Income	-3.25M	-2.70M	-2.50M	-2.36M	-10.77M
Balance Sheet
Total Assets	1.33M	3.75M	2.75M	520.77K	1.52M
Cash, Cash Equivalents and Short-Term Investments	125.95K	1.86M	115.38K	164.42K	1.20M
Total Debt	307.74K	394.67K	527.68K	608.47K	1.34M
Total Liabilities	1.37M	1.24M	1.59M	1.03M	2.75M
Stockholders Equity	-38.78K	2.51M	1.16M	-507.86K	-1.22M
Cash Flow
Free Cash Flow	-1.96M	-1.96M	-1.26M	-1.81M	-3.81M
Operating Cash Flow	-1.96M	-1.96M	-1.26M	-1.81M	-3.81M
Investing Cash Flow	0.00	0.00	14.64K	0.00	0.00
Financing Cash Flow	228.43K	3.70M	1.20M	778.00	4.89M

Sona Nanotech Inc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.40
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:SONA, the sentiment is Negative. The current price of 0.4 is above the 20-day moving average (MA) of 0.38, below the 50-day MA of 0.42, and below the 200-day MA of 0.52, indicating a bearish trend. The MACD of -0.01 indicates Negative momentum. The RSI at 48.68 is Neutral, neither overbought nor oversold. The STOCH value of 62.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:SONA.

Sona Nanotech Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BUX	48 Neutral	C$63.05M	-32.47	―	―	-21.89%	26.36%
SONA	42 Neutral	C$36.60M	-21.43	-434.25%	―	―	10.97%
EBM	42 Neutral	C$37.89M	-144.91	―	―	-9.02%	14.29%
MIR	42 Neutral	C$45.61M	-17.16	―	―	-41.70%	-35.42%

Sona Nanotech Inc Corporate Events

Sona Nanotech to Detail Promising Cancer Therapy Data in Investor Webinar

Sona Nanotech will host an investor webinar on March 18 to present follow‑up data from its first‑in‑human study of Targeted Hyperthermia Therapy in ten late‑stage melanoma patients who had failed standard immunotherapy. Led by principal investigator Dr. Carlos Rojas and joined by Sona’s leadership, the session will review safety, tolerability and efficacy findings, including an 80% clinical response rate, 60% complete tumor clearance in two weeks, and evidence of an abscopal effect in an untreated secondary tumor.

The company plans to make a recording of the event available on its website, signaling an effort to increase transparency and engagement with investors as it advances its novel cancer treatment platform. The promising early results, particularly the immune responses in most treated tumors, highlight the potential of Targeted Hyperthermia Therapy to strengthen Sona’s position in oncology innovation and could influence stakeholder expectations regarding its clinical and commercial trajectory.

The most recent analyst rating on (TSE:SONA) stock is a Hold with a C$0.34 price target. To see the full list of analyst forecasts on Sona Nanotech Inc stock, see the TSE:SONA Stock Forecast page.